



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Tina Jost
✉ tina.jost@uk-erlangen.de

RECEIVED 08 April 2025

ACCEPTED 09 April 2025

PUBLISHED 23 April 2025

CITATION

Meidenbauer J, Wachter M, Schulz SR, Mostafa N, Zülch L, Frey B, Fietkau R, Gaipf US and Jost T (2025) Corrigendum: Inhibition of ATM or ATR in combination with hypo-fractionated radiotherapy leads to a different immunophenotype on transcript and protein level in HNSCC. *Front. Oncol.* 15:1607882. doi: 10.3389/fonc.2025.1607882

COPYRIGHT

© 2025 Meidenbauer, Wachter, Schulz, Mostafa, Zülch, Frey, Fietkau, Gaipf and Jost. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](#). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Inhibition of ATM or ATR in combination with hypo-fractionated radiotherapy leads to a different immunophenotype on transcript and protein level in HNSCC

Julia Meidenbauer^{1,2,3}, Matthias Wachter^{1,2,3}, Sebastian R. Schulz⁴, Nada Mostafa^{1,2,3}, Lilli Zülch^{1,2,3}, Benjamin Frey^{1,2,3,5,6}, Rainer Fietkau^{2,3,5,6}, Udo S. Gaipf^{1,2,3,5,6} and Tina Jost^{1,2,3*}

¹Translational Radiobiology, Department of Radiation Oncology, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ²Department of Radiation Oncology, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany,

³Comprehensive Cancer Center Erlangen-Europäische Metropolregion Nürnberg (EMN), Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ⁴Division of Molecular Immunology, Internal Medicine III, University Hospital Erlangen, Nikolaus-Fiebiger Center, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany, ⁵Deutsches Zentrum Immuntherapie, Uniklinikum Erlangen, Erlangen, Germany, ⁶FAU Profile Center Immunomedicine Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

KEYWORDS

HNSCC, DNA damage repair, kinase inhibitors, immunomodulation, ATM inhibition, ATR inhibition

A Corrigendum on

Inhibition of ATM or ATR in combination with hypo-fractionated radiotherapy leads to a different immunophenotype on transcript and protein level in HNSCC

by Meidenbauer J, Wachter M, Schulz SR, Mostafa N, Zülch L, Frey B, Fietkau R, Gaipf US and Jost T (2024) *Front. Oncol.* 14:1460150. doi: 10.3389/fonc.2024.1460150

In the published article, there was an error in the **Funding** statement. In the Funding statement one sentence was missing. The correct **Funding** statement appears below.

“The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by the DFG Doctoral Training Group 2599 “Fine-Tuners of the Adaptive Immune Response” and partly by the Interdisciplinary Center for Clinical Research (IZKF) in Erlangen. The present work was performed by Julia Meidenbauer in (partial) fulfilment of the requirements for obtaining the degree “Dr. med.” at the Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU).”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.